Serum amyloid A as a potent therapeutic marker in a refractory patient with polymyalgia rheumatica

11Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

We report a patient with polymyalgia rheumatica (PMR) who showed a relapse soon after tapering of oral prednisolone. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were quickly normalized after the re-increase in oral prednisolone, and muscle pain and stiffness gradually improved in parallel with a decrease in serum amyloid A (SAA). Flow cytometry simultaneously demonstrated an increase in CD8+CD25+ cells and a decrease in CD4+CD25+ cells and CD4+CD45RA+ cells. When clinical symptoms remain with negative results for CRP and ESR even after the start of corticosteroid treatment, SAA might be a potent therapeutic marker for disease activity in PMR. Copyright © 2005 by The Japanese Society of Internal Medicine.

Cite

CITATION STYLE

APA

Shimojima, Y., Matsuda, M., Gono, T., Ishii, W., & Ikeda, S. I. (2005). Serum amyloid A as a potent therapeutic marker in a refractory patient with polymyalgia rheumatica. Internal Medicine, 44(9), 1009–1012. https://doi.org/10.2169/internalmedicine.44.1009

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free